{"filing":{"accession_number":"0001178913-26-004604","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-09-25","report_date":"2026-09-25","primary_document":"zk2636155.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004604/zk2636155.htm"},"events":[{"id":35096,"run_id":32319,"accession_number":"0001178913-26-004604","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This is a clear disclosure of shareholder vote results under Item 5.07. The filing reports the outcomes of two proposals voted on at an extraordinary general meeting on September 23, 2026: an Authorized Share Capital Increase Proposal (rejected 75.4% against) and a Reverse Share Split Proposal (rejected 74.1% against). Both proposals failed to achieve majority approval. The rejection of these capital structure proposals is material to investors as it affects the Company's ability to execute planned financing or restructuring strategies.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-25","form":"8-K","submitted_at":null,"items":[{"id":39028,"accession_number":"0001178913-26-004604","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder vote results under Item 5.07. The filing reports the outcomes of two proposals voted on at an extraordinary general meeting on September 23, 2026: an Authorized Share Capital Increase Proposal (rejected 75.4% against) and a Reverse Share Split Proposal (rejected 74.1% against). Both proposals failed to achieve majority approval. The rejection of these capital structure proposals is material to investors as it affects the Company's ability to execute planned financing or restructuring strategies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T20:10:37.337942+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39028,"accession_number":"0001178913-26-004604","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder vote results under Item 5.07. The filing reports the outcomes of two proposals voted on at an extraordinary general meeting on September 23, 2026: an Authorized Share Capital Increase Proposal (rejected 75.4% against) and a Reverse Share Split Proposal (rejected 74.1% against). Both proposals failed to achieve majority approval. The rejection of these capital structure proposals is material to investors as it affects the Company's ability to execute planned financing or restructuring strategies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T20:10:37.337942+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-25"}]}